365 related articles for article (PubMed ID: 15710577)
41. Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
Millot F; Esperou H; Bordigoni P; Dalle JH; Michallet M; Michel G; Bourhis JL; Kuenz M; Blaise D; Garban F; Plouvier E; Rome A; Guilhot J; Guilhot F
Bone Marrow Transplant; 2003 Nov; 32(10):993-9. PubMed ID: 14595387
[TBL] [Abstract][Full Text] [Related]
42. The impact of HLA matching on long-term transplant outcome after allogeneic hematopoietic stem cell transplantation for CLL: a retrospective study from the EBMT registry.
Michallet M; Sobh M; Milligan D; Morisset S; Niederwieser D; Koza V; Ruutu T; Russell NH; Verdonck L; Dhedin N; Vitek A; Boogaerts M; Vindelov L; Finke J; Dubois V; van Biezen A; Brand R; de Witte T; Dreger P;
Leukemia; 2010 Oct; 24(10):1725-31. PubMed ID: 20703257
[TBL] [Abstract][Full Text] [Related]
43. KIR2DS5 is associated with leukemia free survival after HLA identical stem cell transplantation in chronic myeloid leukemia patients.
van der Meer A; Schaap NP; Schattenberg AV; van Cranenbroek B; Tijssen HJ; Joosten I
Mol Immunol; 2008 Aug; 45(13):3631-8. PubMed ID: 18555529
[TBL] [Abstract][Full Text] [Related]
44. High CD4/CD8 ratio in allografts predicts adverse outcomes in unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation for chronic myeloid leukemia.
Xu LP; Luo XH; Chang YJ; Liu DH; Liu KY; Chen YH; Huang XJ
Ann Hematol; 2009 Oct; 88(10):1015-24. PubMed ID: 19319533
[TBL] [Abstract][Full Text] [Related]
45. Relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: outcome and prognostic factors: the Chronic Myeloid Leukemia Subcommittee of the GETH (Grupo Español de Trasplante Hemopoyético).
Martínez C; Gomez V; Tomás JF; Parody R; Sureda A; Sanz G; Cañizo C; Díez JL; Boqué C;
Bone Marrow Transplant; 2005 Aug; 36(4):301-6. PubMed ID: 15968278
[TBL] [Abstract][Full Text] [Related]
46. A low body mass index is correlated with poor survival after allogeneic stem cell transplantation.
Le Blanc K; Ringdén O; Remberger M
Haematologica; 2003 Sep; 88(9):1044-52. PubMed ID: 12969813
[TBL] [Abstract][Full Text] [Related]
47. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
Huisman C; Meijer E; Petersen EJ; Lokhorst HM; Verdonck LF
Biol Blood Marrow Transplant; 2008 Feb; 14(2):181-6. PubMed ID: 18215778
[TBL] [Abstract][Full Text] [Related]
48. Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients.
Burke MJ; Trotz B; Luo X; Weisdorf DJ; Baker KS; Wagner JE; Verneris MR
Bone Marrow Transplant; 2009 Aug; 44(3):169-74. PubMed ID: 19204709
[TBL] [Abstract][Full Text] [Related]
49. [Influence of graft-versus-host disease on long-term survival of 26 patients with hematologic malignancies after transplantation].
Lin Q; Dong M; Wang QM; Wen JY; Wu XY
Ai Zheng; 2006 Oct; 25(10):1261-5. PubMed ID: 17059772
[TBL] [Abstract][Full Text] [Related]
50. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis.
Gratwohl A; Stern M; Brand R; Apperley J; Baldomero H; de Witte T; Dini G; Rocha V; Passweg J; Sureda A; Tichelli A; Niederwieser D;
Cancer; 2009 Oct; 115(20):4715-26. PubMed ID: 19642176
[TBL] [Abstract][Full Text] [Related]
51. Long term follow up after allogeneic stem cell transplantation for chronic myelogenous leukemia.
Reiter E; Greinix HT; Brugger S; Keil F; Rabitsch W; Mannhalter C; Schwarzinger I; Höcker P; Fischer G; Dieckmann K; Hinterberger W; Linkesch W; Schneider B; Lechner K; Kalhs P
Bone Marrow Transplant; 1998 Dec; 22 Suppl 4():S86-8. PubMed ID: 9916646
[TBL] [Abstract][Full Text] [Related]
52. Outcome of 125 children with chronic myelogenous leukemia who received transplants from unrelated donors: the Japan Marrow Donor Program.
Muramatsu H; Kojima S; Yoshimi A; Atsuta Y; Kato K; Nagatoshi Y; Inoue M; Koike K; Kawase T; Ito M; Kurosawa H; Tanizawa A; Tono C; Hamamoto K; Hotta N; Watanabe A; Morishima Y; Kawa K; Shimada H
Biol Blood Marrow Transplant; 2010 Feb; 16(2):231-8. PubMed ID: 19800016
[TBL] [Abstract][Full Text] [Related]
53. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation.
Weisser M; Tischer J; Schnittger S; Schoch C; Ledderose G; Kolb HJ
Haematologica; 2006 May; 91(5):663-6. PubMed ID: 16627251
[TBL] [Abstract][Full Text] [Related]
54. Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia.
Mittal P; Saliba RM; Giralt SA; Shahjahan M; Cohen AI; Karandish S; Onida F; Beran M; Champlin RE; de Lima M
Bone Marrow Transplant; 2004 May; 33(10):1005-9. PubMed ID: 15048141
[TBL] [Abstract][Full Text] [Related]
55. Allogeneic bone marrow transplant or second autograft in patients with acute leukemia who relapse after an autograft. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).
Ringdén O; Labopin M; Frassoni F; Sanz G; Demeocq F; Prentice H; Cahn JY; Barbui T; Meloni G; Schaefer U; Reiffers J; Gorin N
Bone Marrow Transplant; 1999 Aug; 24(4):389-96. PubMed ID: 10467328
[TBL] [Abstract][Full Text] [Related]
56. Predicting factors for admission to an intensive care unit and clinical outcome in pediatric patients receiving hematopoietic stem cell transplantation.
Diaz MA; Vicent MG; Prudencio M; Rodriguez F; Marin C; Serrano A; Sevilla J; Casado J; Madero L
Haematologica; 2002 Mar; 87(3):292-8. PubMed ID: 11869942
[TBL] [Abstract][Full Text] [Related]
57. Risk factors for late infections after allogeneic hematopoietic stem cell transplantation from a matched related donor.
Robin M; Porcher R; De Castro Araujo R; de Latour RP; Devergie A; Rocha V; Larghero J; Adès L; Ribaud P; Mary JY; Socié G
Biol Blood Marrow Transplant; 2007 Nov; 13(11):1304-12. PubMed ID: 17950917
[TBL] [Abstract][Full Text] [Related]
58. The belgian experience in unrelated donor bone marrow transplantation: identification of center experience as an important prognostic factor.
Dresse MF; Boogaerts M; Vermylen C; Noens L; Ferrant A; Schots R; Doyen C; Bron D; Berneman Z; Ferster A; Benoit Y; Demuynck H; Beguin Y
Haematologica; 1999 Jul; 84(7):637-42. PubMed ID: 10406907
[TBL] [Abstract][Full Text] [Related]
59. Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation.
Wright MP; Shepherd JD; Barnett MJ; Nantel SH; Sutherland HJ; Toze CL; Hogge DE; Nevill TJ; Song KW; Abou Mourad YR; Narayanan S; Power MM; Smith CA; Forrest DL
Biol Blood Marrow Transplant; 2010 May; 16(5):639-46. PubMed ID: 20005967
[TBL] [Abstract][Full Text] [Related]
60. Allogeneic bone marrow transplantation for chronic myeloid leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation (EBMT).
Gratwohl A; Hermans J
Bone Marrow Transplant; 1996 May; 17 Suppl 3():S7-9. PubMed ID: 8769691
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
